NCT07807228 Changes in Skin Myco- and Microbiome After Lebrikizumab Treatment
| NCT ID | NCT07807228 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Bispebjerg and Frederiksberg |
| Condition | Atopic Dermatitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-06-05 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-06-05 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to characterize the skin myco- and microbiome of patients with atopic dermatitis before and after initiation of treatment with lebrikizumab. The main questions it aims to answer are: Does the skin mycobiome change with treatment? Does the skin microbiome change with treatment? Does the abundance of Staphylococcus species change with treatment?
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years diagnosed with atopic dermatitis and initiating treatment with lebrikizumab Exclusion Criteria: * Previous treatment with lebrikizumab * Current treatment with other biologics or JAK-inhibitors * Hypersensitivity to lebrikizumab or any of its constituents * Pregnancy or breastfeeding * Active helminth infection
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07807228 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07807228 currently recruiting?
Yes, NCT07807228 is actively recruiting participants. Contact the research team at ida.marie.nedergaard.thomsen.01@regionh.dk for enrollment information.
Where is the NCT07807228 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT07807228 clinical trial?
NCT07807228 is sponsored by University Hospital Bispebjerg and Frederiksberg. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.